FLT3LG and acute myeloid leukemia: The panel of early biomarkers, including CBC, DNA breaks by Comet assay, AML, FLT3-L, inflammation cytokines as IL1B, IL6, IL 8, zinc and copper concentrations, were validated on cancer patients undergoing radiotherapy (RT) before and 3 h after the first fraction of RT treatment.